RYTM
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Rhythm Pharmaceuticals launches IMCIVREE (setmelanotide) commercially in Japan for acquired hypothalamic obesityOct 14, 2026
- Rhythm Pharmaceuticals receives Health Canada approval for IMCIVREE (setmelanotide) for weight management in adults and children aged 4 and older with acquired hypothalamic obesitySep 22, 2026
- Rhythm Pharmaceuticals received MHLW approval for IMCIVREE (setmelanotide) in Japan for patients with acquired hypothalamic obesityAug 24, 2026
- Rhythm Pharmaceuticals received expanded U.K. marketing authorization for IMCIVREE to treat obesity and control hunger in patients with acquired hypothalamic obesityAug 11, 2026
- Rhythm Pharmaceuticals reported preliminary Phase 2 data showing a positive efficacy signal for RM-718 in acquired hypothalamic obesityAug 4, 2026